Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embla Medical hfOSSFF 91 EV-to-FCF is 22.41 as of Jul. 14, 2026, which is 51% below its 10-year median of 45.63. GuruFocus rates OSSFF with a GF Score™ of 91/100 and a GF Value™ of $5.48. The stock has 2 warning signs investors should review. Among 416 Medical Devices & Instruments companies, Embla Medical hf ranks better than 50.72% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Embla Medical hf's Enterprise Value is $2,162.7 Mil.
Embla Medical hf's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $96.5 Mil. Therefore, Embla Medical hf's EV-to-FCF for today is 22.41.
The historical rank and industry rank for Embla Medical hf's EV-to-FCF or its related term are showing as below:
OSSFF'
s EV-to-FCF Range Over the Past 10 Years
Min: 21.32 Med: 45.63 Max: 79.56
Current: 23.09
During the past 13 years, the highest EV-to-FCF of Embla Medical hf was 79.56. The lowest was 21.32. And the median was 45.63.
OSSFF's EV-to-FCF is ranked better than 50.72% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.305
vs OSSFF: 23.09
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Embla Medical hf (OTCPK:OSSFF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Embla Medical hf's PE Ratio (TTM) for today is calculated as:
Embla Medical hf's share price for today is $4.15.
Embla Medical hf's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.202.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Embla Medical hf EV-to-FCF Related Terms
Embla Medical hf EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's EV-to-FCF falls into.
Embla Medical hf's current Enterprise Value is $2,162.7 Mil.
Embla Medical hf's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $96.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf (OSSFF) has a EV-to-FCF of 22.41 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Embla Medical hf and its competitors. This is 51% below median its historical median of 45.63. Over the past decade, Embla Medical hf's EV-to-FCF has ranged from 21.32 to 79.56. According to the industry distribution chart, Embla Medical hf ranks #205 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 49.3%.
Is Embla Medical hf's EV-to-FCF too high?
Embla Medical hf's current EV-to-FCF of 22.41 is 51% below median its 10-year median of 45.63. Over the past 10 years, this metric has ranged from a low of 21.32 to a high of 79.56. The Medical Devices & Instruments industry median EV-to-FCF is 23.31. Embla Medical hf's value of 22.41 is 3.8% below this industry median. Based on the distribution chart, Embla Medical hf ranks #205 out of 416 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #205 out of 416 companies for EV-to-FCF. This puts Embla Medical hf in the upper half of its industry. The industry median EV-to-FCF is 23.31. Embla Medical hf's value of 22.41 is 3.8% below this benchmark. Historically, Embla Medical hf's own EV-to-FCF has ranged from 21.32 to 79.56 over the past decade. While the company's 10-year median is 45.63 vs. the industry median of 23.31, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.31, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current EV-to-FCF of 22.41 is 3.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current EV-to-FCF is 22.41, which is 51% below median its own 10-year median of 45.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current EV-to-FCF of 22.41. The stock's GF Value™ is $5.48, compared to a current price of $4.15 — trading 24.3% below its estimated fair value. The current EV-to-FCF is 22.41, which is 51% below median its 10-year median of 45.63 and 3.8% below the Medical Devices & Instruments industry median of 23.31. Embla Medical hf's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current EV-to-FCF is 22.41 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 24.3% below its estimated GF Value™ of $5.48.
Key valuation signals for OSSFF:
EV-to-FCF: 22.41 (51% below median its 10-year median of 45.63)
GF Value™: $5.48 vs. price of $4.15 (24.3% below fair value)
Industry Position: 3.8% below the Medical Devices & Instruments median (#205 of 416)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
91GF Score
Get the complete analysis for OSSFF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
